Interference No. 103,675
meeting summary.
According to Dr. Chen's uncorroborated testimony, he
prepared additional samples of "compounds within the counts" in May
1992 (CX 74); December 1992 (CX 78) 13; and January 1993 (CX 79).
According to Dr. Chen's further uncorroborated testimony, Ms. Wei, at
his direction prepared additional samples for testing in April 1992.
Dr. Chen submitted a sample of the compound along with a submission
form to the Compound Control Department (CX 86). The compound was
assigned Bristol compound number BMS-183821-01 (lot number 002). In
May/June 1992, in vivo experiments were started by injecting compound
samples into cancer-implanted mice (CR 159; CX 241-243). According to
Dr. Chen's uncorroborated testimony, he received the results of the in
vivo testing by November 1992 (CR 78).
In February 1992, the Compound Control Department assigned
the compound Bristol compound number BMS-183821 (CX 70). See, also,
page 134, ¶403 of Chen et al.'s brief.
It is difficult to understand how Dr. Chen prepared
"starting materials" for the procedure in his earlier numbered
notebook based on entries in subsequently numbered notebooks,
especially when the date of completion of the procedure in CX 61 is
13 As a "protected" analog of Taxol the compound described in
CX 78 is not a compound within any count.
121
Page: Previous 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 Next
Last modified: November 3, 2007